3 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 3 Not applicable, 3 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Terminated 2, Not yet recruiting 1 |
| Phase 4 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow SCF Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota Omega-3 monoglyceride based topical treatment - Eczema | Not applicable | Not yet recruiting | SCF Pharma | 10 | 2026-05-04 | 2026-05-13 |
| Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema Omega-3 monoglyceride based topical Serum and cream of formulation A (light), Omega-3 monoglyceride based topical Serum and cream of formulation B (rich) - Eczema | Not applicable | Terminated | SCF Pharma | 7 | 2023-12-20 | 2026-04-22 |
| Glyceryl Eicosapentaenoate Based Topic Products as an Irritant-free Cream and Serum for Hydration of Sensitive Skin Glyceryl Eicosapentaenoate serum, Glyceryl Eicosapentaenoate Cream A, Glyceryl Eicosapentaenoate Cream B - Skin Dryness | Not applicable | Terminated | SCF Pharma | 21 | 2023-07-25 | 2026-04-21 |
| Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. Eicosapentaenoic acid monoglycerid (MAG-EPA) - Inflammation | Phase 4 | Completed | SCF Pharma | 30 | 2021-04-21 | 2023-11-27 |
| Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA) MAG-EPA/MAG-DHA, TG-EPA/TG-DHA, EE-EPA/EE-DHA - Healthy Adults | Phase 4 | Completed | SCF Pharma | 36 | 2019-12-18 | 2021-04-29 |
| Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC). MAG-SPM treatment on isolated PBMC cells, Isolated PBMC cells without treatment. - Resolution of Inflammation, Reduction of Cell Proliferation | Recruiting | SCF Pharma | 200 | 2019-03-12 | 2026-04-17 | |
| Effect of Omega-3 Index on Cellular Metabolism and Quality of Life MAG-EPA - Healthy | Phase 4 | Completed | SCF Pharma | 16 | 2017-10-02 | 2019-04-04 |
| Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) MAG-DHA, Placebo - Cystic Fibrosis | Phase 2 | Terminated | SCF Pharma | 11 | 2015-10-01 | 2017-10-04 |
Dermatitis (3) · Eczema (3) · Cystic Fibrosis (1) · Inflammation (1)
1-eicosapentaenoylglycerol (2) · Light (1) · Therapeutics (1) · docosahexaenoic acid monoacylglyceride (1)
Canada (8)
Samuel Fortin, PhD (2) · Anne-Julie Landry, MSc (1) · Samuel C Fortin, PhD (1) · Samuel Fortin, Ph.D (1) · Samuel P Fortin, Ph.D (1) · Samuel P Fortin, PhD (1)